VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

9629	Companies
191456	Keywords
122915	Articles
102031	Press releases

Home
Companies
VALNEVA

BRIEF

published on 01/09/2026 at 07:05, 2 days 12 hours ago

Valneva Engages Investors at J.P. Morgan Healthcare Conference

Valneva Investor Meetings Lyme Disease Vaccine J.P. Morgan Conference Vaccine Portfolio
PRESS RELEASE

published on 01/09/2026 at 07:00, 2 days 12 hours ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Valneva SE to meet with investors at the J.P. Morgan Healthcare Conference to discuss upcoming catalysts from its clinical development pipeline and commercial portfolio of vaccines. Company specializes in prophylactic vaccines for infectious diseases

Valneva SE Prophylactic Vaccines J.P. Morgan Healthcare Conference Vaccine Company Clinical Development Pipeline
BRIEF

published on 12/31/2025 at 17:50, 11 days 1 hour ago

Valneva and Serum Institute End Chikungunya Vaccine Collaboration

Public Health Valneva License Agreement Chikungunya Vaccine Serum Institute
PRESS RELEASE

published on 12/31/2025 at 17:45, 11 days 2 hours ago

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Valneva and Serum Institute of India mutually agree to discontinue chikungunya vaccine license. Valneva aims for direct control over supply chain and access to high-risk regions

Valneva License Agreement CEPI Chikungunya Vaccine Serum Institute Of India
BRIEF

published on 12/10/2025 at 17:50, 1 month 1 day ago

Valneva obtains positive results in Phase 2 for the chikungunya vaccine in children

Valneva Safety Vaccine Phase 2 Chikungunya
BRIEF

published on 12/10/2025 at 17:50, 1 month 1 day ago

Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children

Valneva SE Phase 2 Study Children's Health Chikungunya Vaccine Vaccine Safety
PRESS RELEASE

published on 12/10/2025 at 17:45, 1 month 1 day ago

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
Valneva reports positive final phase 2 antibody persistence and safety results for children with its Chikungunya vaccine IXCHIQ®. Twelve-month data supports full dose selection for Phase 3 trial

Phase 3 Trial Valneva Vaccine Chikungunya Antibody Persistence
BRIEF

published on 12/05/2025 at 18:39, 1 month 6 days ago

Valneva Updates Share and Voting Rights as of November 2025

Stock Options Euronext Paris Voting Rights Valneva Double Voting Rights
BRIEF

published on 12/05/2025 at 18:39, 1 month 6 days ago

VALNEVA: Declaration of Shares and Voting Rights

Euronext Paris Voting Rights Ordinary Shares Valneva 2025
PRESS RELEASE

published on 12/05/2025 at 18:34, 1 month 6 days ago

VALNEVA Declaration of shares and voting rights: November 30, 2025
VALNEVA declares changes in shares and voting rights, including double voting rights granted on ordinary shares and transfer into bearer form

Euronext Paris Voting Rights Shares Valneva Double Voting Rights

Accesswire

Published on 01/10/2026 at 05:10, 1 day 14 hours ago

Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 19 hours ago

Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 1 day 20 hours ago

Sun Peak Metals Grants Stock Options
Published on 01/09/2026 at 23:30, 1 day 20 hours ago

Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 1 day 20 hours ago

Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction

View all ACCESSWIRE

EQS Group

Published on 01/10/2026 at 21:25, 22 hours 20 minutes ago

CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 6 hours ago

SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 1 day 21 hours ago

Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 1 hour ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/09/2026 at 18:19, 2 days 1 hour ago

EQS-Adhoc: BayWa AG: Change in the Board of Management of BayWa AG

Les Echos

Published on 01/09/2026 at 18:30, 2 days 1 hour ago

H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 2 hours ago

January 2026
Published on 01/09/2026 at 17:45, 2 days 2 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 2 hours ago

Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 2 days 22 hours ago

Biannual report on SEB S.A.’S liquidity agreement

View all LES ECHOS COMFI WIRE